Factors associated with health status and exacerbations in COPD maintenance therapy with dry powder inhalers

Funding Information: J.K. reports grants, personal fees and non-financial support from AstraZeneca, GSK and Boehringer Ingelheim; grants and personal fees from Chiesi Pharmaceuticals and TEVA; grants from Mundipharma; personal fees from MSD and COVIS Pharma; and also holds 72.5% of shares in the General Practitioners Research Institute. H.W. has received grants from Boehringer Ingelheim, which is the financial and scientific partner of GPRI for the submitted study, and from AstraZeneca, Novartis and Chiesi for scientific projects in the area of COPD/asthma. S.B.-A. has received grants from TEVA, and personal fees from TEVA, Boehringer Ingelheim, AstraZeneca, GSK, Sanofi and Mylan. J.C.d.S. reports or personal fees from AstraZeneca, Bial, Boehringer Ingelheim, GSK, Medinfar, Mundipharma and Sanofi. B.C. received honorarium from GSK and Sanofi. J.v.C., L.D., I.v.G.-P., I.v.d.H., Y.J., M.K., B.M., K.S., N.S., M.H., B.M. and M.T.L. were employed by General Practitioners Research Institute (GPRI) at the time of the study. In the past three years (2019–2021), GPRI conducted investigator- and sponsor-initiated research funded by non-commercial organizations, academic institutes, and pharmaceutical companies (including AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Mundipharma, Novartis, and Teva). R.D. has received grants and personal fees from TEVA, Boehringer Ingelheim, AstraZeneca, GSK, Chiesi, Focus Care, and Glenmark. R.G. has received personal fees from AstraZeneca, GSK and Chiesi. E.D. holds 27.5% of shares in the General Practitioners Research Institute. M.G.P. receives grants from AstraZeneca, GSK and Boehringer Ingelheim. A.G. and A.d.l.H. are employees of Boehringer Ingelheim. F.L. received grants and personal fees from GSK, personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Menarini International, Novartis, Orion, and Trudell International, outside the submitted work. T.M. is an Assoicate Editor at npj Primary Care Respiratory Medicine. J.M. received grants from Boehringer Ingelheim, during the conduct of the study; and grants from AstraZeneca, Chiesi, Novartis, and GSK, outside the submitted work. D.P. reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Theravance and Zentiva (Sanofi Generics); grants from the British Lung Foundation, Respiratory Effectiveness Group, UK National Health Service, and AKL Research and Development Ltd; personal fees from Cipla, GlaxoSmithKline, Kyorin, Merck, Mundipharma, Airway Vista Secretariat, EPG Communication Holdings Ltd, FIECON Ltd, Fieldwork International, OM Pharma SA, PeerVoice, Phadia AB, Spirosure Inc, Strategic North Limited, Synapse Research Management Partners S.L., Talos Health Solutions, and WebMD Global LLC; non-financial support from Efficacy and Mechanism Evaluation programme and Health Technology Assessment; stock/stock options from AKL Research and Development Ltd, which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 92.61% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); and 5% shareholding in Timestamp, which develops adherence monitoring technology. M.R.-R. receives grants and personal fees from AstraZeneca and GSK; and personal fees from Boehringer Ingelheim, Chiesi, Menarini, Mundipharma, Novartis, Pfizer, TEVA and BIAL. I.T. reports grants and personal fees from GSK, AstraZeneca, Boehringer Ingelheim, Menarini, Novartis, Chiesi and Elpen. O.U. reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Edmond Pharma, Chiesi and GSK; grants from Edmond Pharma; and personal fees from Napp, Mundipharma, Sandoz, Takeda, Cipla, COVIS, Novartis, Mereobiopharma, Orion, and Menarini. S.B.-A. and T.M. are Associate Editors at npj Primary Care Respiratory Medicine, and I.T. is Editor in Chief. These authors were not involved in the journal’s review of, or decisions related to, this manuscript.Peer reviewedPublisher PD

Search for New Particles Decaying to Dijets at CDF

We have used 106 pb^-1 of data collected with the Collider Detector at Fermilab to search for new particles decaying to dijets. We exclude at the 95% confidence level models containing the following new particles: axigluons and flavor universal colorons with mass between 200 and 980 GeV/c, excited quarks with mass between 80 and 570 GeV/c^2 and between 580 and 760 GeV/c^2, color octet technirhos with mass between 260 and 480 GeV/c^2, W' bosons with mass between 300 and 420 GeV/c^2, and E_6 diquarks with mass between 290 and 420 GeV/c^2.Comment: 18 pages, 4 figures, 1 table. Submitted to Physical Review D Rapid Communications. Postscript file of paper is also available at http://www-cdf.fnal.gov/physics/pub97/cdf3276_dijet_search_prd_rc.p

Relationship between the Clinical Frailty Scale and short-term mortality in patients ≥ 80 years old acutely admitted to the ICU: a prospective cohort study.

BACKGROUND: The Clinical Frailty Scale (CFS) is frequently used to measure frailty in critically ill adults. There is wide variation in the approach to analysing the relationship between the CFS score and mortality after admission to the ICU. This study aimed to evaluate the influence of modelling approach on the association between the CFS score and short-term mortality and quantify the prognostic value of frailty in this context. METHODS: We analysed data from two multicentre prospective cohort studies which enrolled intensive care unit patients ≥ 80 years old in 26 countries. The primary outcome was mortality within 30-days from admission to the ICU. Logistic regression models for both ICU and 30-day mortality included the CFS score as either a categorical, continuous or dichotomous variable and were adjusted for patient's age, sex, reason for admission to the ICU, and admission Sequential Organ Failure Assessment score. RESULTS: The median age in the sample of 7487 consecutive patients was 84 years (IQR 81-87). The highest fraction of new prognostic information from frailty in the context of 30-day mortality was observed when the CFS score was treated as either a categorical variable using all original levels of frailty or a nonlinear continuous variable and was equal to 9% using these modelling approaches (p < 0.001). The relationship between the CFS score and mortality was nonlinear (p < 0.01). CONCLUSION: Knowledge about a patient's frailty status adds a substantial amount of new prognostic information at the moment of admission to the ICU. Arbitrary simplification of the CFS score into fewer groups than originally intended leads to a loss of information and should be avoided. Trial registration NCT03134807 (VIP1), NCT03370692 (VIP2)

Further Properties of High-Mass Multijet Events at the Fermilab Proton-Antiproton Collider

The properties of high-mass multijet events produced at the Fermilab proton-antiproton collider are compared with leading order QCD matrix element predictions, QCD parton shower Monte Carlo predictions, and the predictions from a model in which events are distributed uniformly over the available multibody phase-space. Multijet distributions corresponding to (4N-4) variables that span the N-body parameter space are found to be well described by the QCD calculations for inclusive three-jet, four-jet, and five-jet events. The agreement between data, QCD Matrix Element calculations, and QCD parton shower Monte Carlo predictions suggests that 2 -> 2 scattering plus gluon radiation provides a good first approximation to the full LO QCD matrix element for events with three, four, or even five jets in the final state.Comment: 49 pages with 19 figures. Submitted to Phys. Rev. D. PostScript with full resolution figures also available at http://www-cdf.fnal.gov/physics/pub96/cdf3480_multijet_prd_draft3.p

Measurement of correlated μ−overlineb\mu - {overline b} jet cross sections in ppˉp {\bar p} collisions at s=1.8\sqrt{s}=1.8 TeV

We report on measurements of differential $\mu - {\bar b}$ cross sections, where the muon is from a semi-leptonic $b$ decay and the ${\bar b}$ is identified using precision track reconstruction in jets. The semi-differential correlated cross sections, d$\sigma$/d\Et^{{\bar b}}, d$\sigma$/d\pt^{{\bar b}}, and d$\sigma$/d$\delta\phi(\mu - {\bar b})$ for \pt^{\mu}>~9 GeV/c, $|\eta^{\mu}|$~10 GeV, $|\eta^{{\bar b}}|<$~1.5, are presented and compared to next-to-leading order QCD calculations.Comment: Uses Latex, Article 12 point, figures appended as uuencoded file The full PostScript available via WWW at http://www-cdf.fnal.gov/physics/pub95/cdf3164_mu_bbar_prd_final.p

Measurement of the BB Meson Differential Cross Section, dσ/dpTd\sigma/dp_T, in ppˉp\bar{p} Collisions at s=1.8\sqrt{s} = 1.8 TeV

This paper presents the first direct measurement of the $B$ meson differential cross section, $d\sigma/dp_T$, in $p\bar{p}$ collisions at $\sqrt{s}=1.8$ TeV using a sample of $19.3 \pm 0.7$ pb$^{-1}$ accumulated by the Collider Detector at Fermilab (CDF). The cross section is measured in the central rapidity region $|y| 6.0$ GeV/$c$ by fully reconstructing the $B$ meson decays $B^{+}\to J/\psi K^{+}$ and $B^{0}\to J/\psi K^{*0}(892)$, where $J/\psi \to \mu^+\mu^-$ and $K^{*0} \to K^+ \pi^-$. A comparison is made to the theoretical QCD prediction calculated at next-to-leading order.Comment: 14 pages. Submitted to Phys. Rev. Lett. The postscript file is at http://www-cdf.fnal.gov/physics/pub95/cdf2893_bexcl_xsection.p

The Charge Asymmetry in W-Boson Decays Produced in p-pbar Collisions at sqrt(s) = 1.8 TeV

The charge asymmetry has been measured using $19,039~W$ decays recorded by the CDF detector during the 1992-93 run of the Tevatron Collider. The asymmetry is sensitive to the ratio of $d$ and $u$ quark distributions to $x<0.01$ at $Q^2 \approx M_W^2$, where nonperturbative effects are minimal. It is found that of the two current sets of parton distributions, those of Martin, Roberts and Stirling (MRS) are favored over the sets most recently produced by the CTEQ collaboration. The $W$ asymmetry data provide a stronger constraints on $d/u$ ratio than the recent measurements of $F_2^{\mu n}/F_2^{\mu p}$ which are limited by uncertainties originating from deutron corrections.Comment: to be published in PR

Limits on WWZWWZ and WWγWW\gamma couplings from WWWW and WZWZ production in pp‾p\overline{p} collisions at s=1.8\sqrt{s} = 1.8 TeV

Direct limits are set on $WWZ$ and $WW\gamma$ three-boson couplings in a search for $WW$ and $WZ$ production with high transverse momentum in $p\overline{p}$ collisions at $\sqrt{s} = 1.8$ TeV, using the Collider Detector at Fermilab. The results are in agreement with the SU(2) $\times$ U(1) model of electroweak interactions. Assuming Standard Model $WW\gamma$ coupling, the the limits are interpreted as direct evidence for a non-zero $WWZ$ coupling at subprocess energies near 500 GeV. Alternatively, assumiong identical $WWZ$ and $WW\gamma$ couplings, bounds $-0.11 < \kappa < 2.27$ and $-0.81 < \lambda < 0.84$ are obtained at $95\%$ CL for a form factor scale 1000 GeV.Comment: 16 pages, submitted to PRL, URL: http://www-cdf.fnal.gov/physics/pub95/cdf2951_vvprl.p

Study of ttbar Production in ppbar Collisions Using Total Transverse Energy

We analyze a sample of W + jet events collected with the Collider Detector at Fermilab (CDF) in ppbar collisions at sqrt(s) = 1.8 TeV to study ttbar production. We employ a simple kinematical variable "H", defined as the scalar sum of the transverse energies of the lepton, neutrino and jets. For events with a W boson and four or more jets, the shape of the "H" distribution deviates by 3.8 standard deviations from that expected from known backgrounds to ttbar production. However this distribution agrees well with a linear combination of background and ttbar events, the agreement being best for a top mass of 180 GeV/c^2.Comment: Postscript file (gzip+uuencode). 5-page, two-column PRL format (RevTex). Submitted to Phys. Rev. Lett. 09 June 199

Search For Charged Higgs Decays of the Top Quark Using Hadronic Decays of the Tau Lepton

This Letter describes a direct search for charged Higgs boson production in proton-antiproton collisions at sqrt(s)=1.8 TeV recorded by the Collider Detector at Fermilab. Two-Higgs-doublet extensions to the standard model predict the existence of charged Higgs bosons. In such models, the branching fraction for top quarks B(t --> H b --> tau nu b) can be large. This search uses the hadronic decays of the tau lepton in this channel to significantly extend previous limits on charged Higgs production.Comment: 6pages, 4 figures, 1 table; LaTeX; submitted to PR